Skip to content

Summary

A phase 3, randomised study of neoadjuvant chemotherapy alone versus neoadjuvant chemotherapy plus nivolumab or nivolumab and BMS-986205, followed by continued post-surgery therapy with nivolumab or nivolumab and BMS-986205 in participants with muscle-invasive bladder cancer

Acronym:

CA017-078

ACTRN/NCT /ethics:

NCT03661320

Scientific title:

A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC

Sponsor / Cooperative group

Bristol-Myers Squibb

Trial & Patient Characteristics

Cancer TypeBladder
Trial TypeTreatment
PhasePhase III
Age Range18+ years
SexBoth
Tumour StreamBladder
Cancer StageAll stages
Anticipated Start Date2019-07-01
Anticipated End Date-

Participating Hospitals

HospitalCalvary North Adelaide Hospital
Clinical Trial CoordinatorJulie Rowe
Emailjulie.rowe@calvarycare.org.au
Phone08 8239 9536
Principal InvestigatorDr Rohit Joshi
Recruitment StatusRecruiting